Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04960514 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Decision Impact Trial of KidneyIntelX

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Nov 1, 2023 to Dec 1, 2023
    • Site details revised
    v4
  3. Primary completion date: Nov 1, 2022 to Nov 1, 2023v3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2022 to Nov 1, 2022
    • Start date changed from estimate of Oct 1, 2021 to Nov 22, 2021
    • Eligibility criteria expanded, about 6 words
    • Study site revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Trial Details
NCT Number NCT04960514
Lead Sponsor Renalytix AI, Inc.
Conditions
(from sponsor)		 Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
Related terms Diabetic Nephropathies, Lymphoma, Follicular, Renal Insufficiency, Chronic
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov